Lv1
55 积分 2021-06-23 加入
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
2个月前
已完结
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
3个月前
已完结
Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis
3个月前
已完结
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
3个月前
已完结
The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer
3个月前
已关闭
THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER
3个月前
已完结
Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98
3个月前
已完结
Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
4个月前
已完结
Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab
6个月前
已完结
A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer
7个月前
已完结
皖公网安备34019202002308
